摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-ethyl-6-methoxypyridin-3-amine | 51468-14-5

中文名称
——
中文别名
——
英文名称
N-ethyl-6-methoxypyridin-3-amine
英文别名
3-Ethylamino-6-methoxy-pyridin;5-ethylamino-2-methoxypyridine;ethyl-(6-methoxy-pyridin-3-yl)-amine
N-ethyl-6-methoxypyridin-3-amine化学式
CAS
51468-14-5
化学式
C8H12N2O
mdl
MFCD11138481
分子量
152.196
InChiKey
JIJIARWSDGCDSX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    254.2±25.0 °C(Predicted)
  • 密度:
    1.067±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.375
  • 拓扑面积:
    34.2
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Identification of amide bioisosteres of triazole Oxytocin antagonists
    摘要:
    A series of amides were investigated as potential bioisosteres of previously reported triazole Oxytocin antagonists. A range of potent analogues were identified, although SAR for potency and selectivity over the related V(1A) and V(2) receptors was found to be somewhat divergent from that observed for the corresponding triazole series. The high synthetic accessibility of this new amide series also facilitated the identification of a range of alternative left hand side (biaryl replacement) substituents which gave good levels of Oxytocin antagonism. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.02.018
  • 作为产物:
    描述:
    N-(6-methoxy-pyridin-3-yl)-acetamide 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃乙醚 为溶剂, 以96%的产率得到N-ethyl-6-methoxypyridin-3-amine
    参考文献:
    名称:
    Identification of a urea bioisostere of a triazole oxytocin antagonist
    摘要:
    A series of azetidine ureas were investigated as potential bioisosteres of previously reported azetidinyltriazole oxytocin antagonists. Although potency was somewhat reduced in several close-in analogues, one compound, 9, was both a potent oxytocin antagonist and demonstrated significant selectivity over the closely related vasopressin V(1A) receptor. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.01.143
点击查看最新优质反应信息

文献信息

  • Cannabinoid receptor ligands and uses thereof
    申请人:Pfizer Inc
    公开号:US20040157839A1
    公开(公告)日:2004-08-12
    Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1
    化合物的化学式(I),其作为大麻素受体配体并在治疗与动物体内大麻素受体介导相关疾病中的用途被描述在此。
  • 氮杂环丁基甲酰胺类衍生物、其制备方法及其 在医药上的应用
    申请人:江苏恒瑞医药股份有限公司
    公开号:CN108689996B
    公开(公告)日:2021-06-29
    本发明涉及氮杂环丁基甲酰胺类衍生物、其制备方法及其在医药上的应用。具体而言,本发明涉及一种通式(I)所示的新的氮杂环丁基甲酰胺类衍生物、其制备方法及其含有该衍生物的药物组合物及其作为治疗剂,特别是作为催产素拮抗剂的用途和在制备用于治疗或预防已知或可显示抑制催产素会产生有益效果的疾病或病症的药物中的用途,其中通式(I)的各取代基与说明书中的定义相同。
  • PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
    申请人:Fink Brian E.
    公开号:US20090048244A1
    公开(公告)日:2009-02-19
    The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    本发明提供公式I化合物及其药学上可接受的盐。公式I化合物抑制生长因子受体的酪氨酸激酶活性,如HER1、HER2和HER4,因此使它们有用作抗增殖剂。公式I化合物也适用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。
  • Benzene, Pyridine, and Pyridazine Derivatives
    申请人:Huang Kenneth He
    公开号:US20080096887A1
    公开(公告)日:2008-04-24
    Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
    本发明公开了式I的化合物和药学上可接受的盐,其中R1、R2、R3、R4、R5、R6、R7、n、Q1、Q2、Q3、Y和X1-X4的定义如本文所述。式I的化合物可用于治疗与细胞增殖有关的疾病和/或疾病,例如癌症、炎症、关节炎、血管生成或类似疾病。本发明还公开了包含本发明化合物的制药组合物和使用这些化合物治疗上述疾病的方法。
  • Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation
    申请人:Edlin Christopher
    公开号:US20070191426A1
    公开(公告)日:2007-08-16
    Compounds of formula (I) or pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type IV (PDE4) and are of use in the treatment of inflammatory and/or allergic diseases.
    化合物I式或其药学上可接受的盐是磷酸二酯酶IV型(PDE4)的抑制剂,可用于治疗炎症和/或过敏性疾病。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-